Critical quality attribute (CQA) assessment is essential in the development of IVT mRNA biotherapeutics to ensure their safety, efficacy, and consistency. Regulatory agencies like the US Pharmacopeia (USP) provide guidelines for evaluating key CQAs, such as identity, content, purity, potency, and safety, throughout the development process. Agilent offers advanced solutions to address these CQAs and help maintain high standards in the IVT mRNA biotherapeutic workflow.
Our comprehensive application compendium features technical overviews and application notes showcasing Agilent automated electrophoresis and LC/MS solutions for reliable CQA assessment throughout the workflow, from DNA starting material to the final drug product.

Explore how our integrated solutions can support your biotherapeutic development and help you achieve regulatory compliance with confidence.
For Research Use Only. Not for use in diagnostic procedures. PR7001-3815
Contact us for questions about the automated electrophoresis systems.